Genetic testing for cystic fibrosis.
OBJECTIVE
To provide health care providers, patients, and the general public with a responsible assessment of the optimal practices for genetic testing for cystic fibrosis (CF).


METHODS
A non-Federal, nonadvocate, 14-member panel representing the fields of genetics, obstetrics, internal medicine, nursing, social work, epidemiology, pediatrics, psychiatry, genetic counseling, bioethics, health economics, health services research, law, and the public. In addition, 21 experts from these same fields presented data to the panel and a conference audience of 500.


METHODS
The literature was searched through Medline, and an extensive bibliography of references was provided to the panel and the conference audience. Experts prepared abstracts with relevant citations from the literature. Scientific evidence was given precedence over clinical anecdotal experience.


METHODS
The panel, answering predefined questions, developed its conclusions based on the scientific evidence presented in open forum and the scientific literature. The panel composed a draft statement that was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference.
D003362:Cost-Benefit Analysis; D003550:Cystic Fibrosis / Q000453:epidemiology / Q000235:genetics* / Q000517:prevention & control* / Q000628:therapy; D006580:Genetic Carrier Screening; D005817:Genetic Counseling; D005820:Genetic Testing / Q000191:economics / Q000379:methods* / Q000592:standards*; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D018579:Patient Selection